Idera Pharmaceuticals, Inc.
TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS

Abstract:

The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.